Psychedelics and biotech company Cybin Inc. CYBN CLXPF is co-sponsoring a new clinical trial that will test the benefits of psilocybin treatment in health workers experiencing COVID-related distress.
The randomized, placebo-controlled trial aims to treat symptoms of depression, anxiety, burnout and PTSD among frontline doctors, nurses and healthcare professionals.
Researchers will apply psychedelics-assisted psychotherapy methods that use psilocybin in conjunction with psychological therapy.
Cybin is sponsoring the trial in a partnership with the University of Washington in Seattle.
The organizations want to ascertain whether psychedelic medicine can help clinicians recover from COVID-related distress, said Dr. Alex Belser, Cybin’s chief clinical officer.
“Our nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest among us. They’re experiencing high levels of anxiety, depression and burnout. Now it’s our turn to help them,” Belser added.
Cybin CEO, Doug Drysdale, said he is proud to be helping front-line healthcare workers.
"We are also delighted and proud to launch EMBARK, a ground-breaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics.”
The EMBARK model will be applied to this study for the first time.
Photo by Science in HD on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.